SCHEMBL6086047

SCHEMBL6086047

CCN[C@@H]1C[C@@H](C)S(=O)(=O)c2sccc21

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CA2 P00918 18/20 0.54
CA1 P00915 3/20 0.54
CA12 O43570 1/20 0.54
CA3 P07451 1/20 0.54
AR P10275 1/20 0.54
CA4 P22748 1/20 0.54
CA6 P23280 1/20 0.54
CA5A P35218 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
CA13 Q8N1Q1 1/20 0.54
CA14 Q9ULX7 1/20 0.54
CA5B Q9Y2D0 1/20 0.54
LMNA P02545 1/20 0.54
TSHR P16473 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12315845 1.00 CA2 (0.54) CA2CA1CA12CA3AR
SCHEMBL13852709 1.00 CA2 (0.54) CA2CA1CA12CA3AR
SCHEMBL4196353 1.00 CA2 (0.54) CA2CA1CA12CA3AR
Hydrochloric Acid SCHEMBL4192529 0.99 CA2 (0.53) CA2CA1CA12CA3AR
Ethylamine SCHEMBL4329115 0.96 CA2 (0.54) CA2CA1CA12CA3AR
SCHEMBL20097750 0.82 CA2 (0.39) CA2CA1CA12CA3AR
SCHEMBL6092290 0.80 CA2 (0.37) CA2CA1CA12CA3AR
SCHEMBL12315839 0.80 CA2 (0.37) CA2CA1CA12CA3AR
SCHEMBL18651228 0.77 CA2 (0.34) CA2CA1CA12CA3AR
SCHEMBL6728246 0.75 CA2 (0.67) CA2CA1CA12CA3AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030250-B2 Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates RAGATIVES, S.L. (ES) 2006-04-18 US disclosed
EP-1329453-B1 METHOD FOR OBTAINING 4-(N-ALKYLAMINE)-5, 6-DIHYDRO-4H-THIENO-(2,3-B)-THIOPYRAN-2-SULFONAMIDE-7, 7-DIOXIDES AND INTERMEDIATE PRODUCTS RAGACTIVES SL (ES) 2004-06-16 EP disclosed
US-20030220509-A1 Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates RAGACTIVES, S.L. 2003-11-27 US disclosed
EP-1329453-A1 METHOD FOR OBTAINING 4-(N-ALKYLAMINE)-5, 6-DIHYDRO-4H-THIENO-(2,3-B)-THIOPYRAN-2-SULFAMIDE-7, 7-DIOXIDES AND INTERMEDIATE PRODUCTS Ragactives, S.L. (ES) 2003-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220509-A1 Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates CA7, CA2, CA4 CA2 2/4885CA1 24/4885CA12 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.